Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report new operative approaches to the treatment of hepatic vein occlusion due to malignant tumors in the liver and their results in four patients. Two patients had hepatoma, one had metastatic melanoma, and one had metastatic leiomyosarcoma. All of them had abdominal pain, abdominal distention secondary to ascites, and massive hepatomegaly. The right lobe and medial segment of the left lobe of the liver were involved in three patients, and the involvement was diffuse throughout the liver in one. Hepatic veins were occluded completely in one patient, and two of three veins were occluded in the others. Two patients were treated by hepatic resection and removal of tumor thrombus from the hepatic vein under isolation-perfusion technique. They lived 18 and six months, respectively, without recurrence of Budd-Chiari syndrome. Tumors in the other patients were diffuse and could not be resected. The hepatic artery was ligated and chemotherapy was given postoperatively. Ascites and abdominal pain disappeared completely in one, who survived 17 months. The other patient had significant palliation and lived nine months.
 ...
PMID:Surgical management of hepatic vein occlusion by tumor: Budd-Chiari syndrome. 19 61

Hepatic artery ligation is useful as a palliation of irressectable hepatic tumors, but does not always produce a satisfactory result. Hepatic tumor with high vascularity is expected to respond more favorably. In this context, primary liver cell carcinoma and carcinoid tumor or leiomyosarcoma of the liver have been satistfactorily treated by hepatic artery ligation. A case is presented of hemangiosarcoma of theliver and spleen treated effectively by hepatic artery ligation, splenectomy, and postoperative intraportal infusion of 5-fluorouracil, as indicated by the regression of hepatic tumors on postoperative scanning and arteriograpms.
 ...
PMID:Hemangiosarcoma of liver and spleen treated by hepatic artery ligation, intraportal infusion chemotherapy, and splenectomy. 98 37

We collected 20 primary liver malignant tumors other than hepatocellular carcinoma from 1968 to 1990; sarcomas from mesenchymal tissue (hepatic leiomyosarcoma, hepatic fibrosarcoma, Kupffer cell sarcoma, hepatic lymphatic sarcoma), two subtypes of hepatocellular carcinoma (fibrolamellar carcinoma and clear cell carcinoma), hepatic carcinoid, squamous carcinoma, etc. Analysis with review of literature is given.
 ...
PMID:[20 rare primary hepatic malignant tumors]. 139 62

Over a 30 month period from 1987 to 1990, selective hepatic cannulation under fluoroscopic control was performed in 57 consecutive patients with primary and secondary malignancies of the liver. Fifty-three patients were subsequently treated using intra-arterial Lipiodol emulsified with epirubicin. The tumours treated were hepatocellular carcinoma (n = 35), metastatic adenocarcinoma (n = 14), intrahepatic cholangiocarcinoma (n = 3) and leiomyosarcoma (n = 1). For hepatocellular carcinoma the cumulative survival was 38% at one year; the median survival was 12.2 months for Stage I, 6.3 months for Stage II and 0.9 months for Stage III tumours. In metastatic disease the cumulative survival was 63% at one year. These data suggest that targeted intra-arterial chemotherapy with Lipiodol-epirubicin is a useful palliative therapy for patients with Stage I and II HCC, and that a controlled trial of this treatment should be undertaken.
 ...
PMID:Selective regional chemotherapy of unresectable hepatic tumours using lipiodol. 165 18

Two-dimensional echocardiography was used to study malignant metastatic neoplasms of the heart and great vessels in 20 patients, 13 males and seven females, whose ages ranged from 15 to 72 years. Five patients had lung cancer; two each had breast cancer, malignant melanoma, hepatoma and one each had gastric cancer, urinary bladder cancer, adrenocortical carcinoma, malignant lymphoma, angiosarcoma, fibrosarcoma, leiomyosarcoma; and two had cancers with unknown primaries. Tumor invasion was demonstrated echocardiographically in the left atrium in one each with breast cancer, fibrosarcoma and gastric cancer; in the right atrium in two with hepatomas; in the right atrium and right ventricle in one patient with adrenocortical carcinoma; in the left ventricle in one with lung cancer; and in the pulmonary artery in one with malignant melanoma. Massive pericardial effusion was observed in 11 of 20 patients; two with pericardial tumors including malignant lymphoma and lung cancer. We conjectured that metastatic tumors in the right cardiac cavities came through the inferior vena cava, and other tumors in the left atrium, left ventricle and pericardium developed from direct extension of the primary lesions. There was an 80% mortality of the patients during the observation period, and the average survival period after the diagnosis of cardiac metastases was 5.5 months. However, one patient was still living after two years of radiation therapy and chemotherapy. Echocardiography proved a useful, non-invasive means for the detection and follow-up observation of metastatic cardiac tumors.
 ...
PMID:[Echocardiography in patients with malignant metastatic neoplasms of the heart and great vessels]. 210 13

A catheter (5Fr) was inserted and placed via the left radial artery in the common or proper hepatic artery for intra-hepato-arterial infusion chemotherapy in 26 cases of liver malignancy. The patients for the chemotherapy included 15 cases of primary hepatocellular carcinoma, five cases of metastatic gastric carcinoma, 3 cases of metastatic colorectal carcinoma, one case of metastatic leiomyosarcoma, one case of metastatic bile duct carcinoma and one case of metastatic melanoma. A large-bore catheter was successfully inserted via the left radial artery, and transcatheter arterial embolization therapy (TAE) was performed on 8 cases during the infusion chemotherapy using the same catheter. One case developed cerebellar infarction after the insertion of the catheter, but no other serious complication developed during the therapy using this technique. It is easy to insert or remove the catheter via the left radial artery. This technique is useful in intra-hepato-arterial infusion chemotherapy on liver malignancy.
 ...
PMID:[Intra-hepato-arterial infusion chemotherapy using catheter inserted and placed in hepatic artery via the left radial artery on liver malignancy]. 215 87

We have treated unresectable liver tumor with intraarterial infusion chemotherapy using an implantable reservoir since 1983. Out of the total 44 cases receiving the chemotherapy during the period from 1983 to February 1989, the evaluation of 8 cases (18.2%) surviving over a year is reported. The 8 cases consist of 3 cases of primary hepatic cancer, 4 cases of metastatic hepatic cancer and 1 case of malignant hemangiopericytoma of pelvis. The cases of primary hepatic cancer are 2 cases of hepatoma (413, 420 days) and 1 case of cancer of bile-duct (400 days). The metastatic cases are 1 case of gastric cancer (826 days), 2 cases of colo-rectal cancer (698, 1080 days) and 1 cases of leiomyosarcoma of small intestine (577 days). A case of malignant hemangiopericytoma of pelvis has survived 4 years and 3 months after the infusion chemotherapy via the internal iliac artery. The two cases of colo-rectal cancer were treated with continuous infusion of FUDR via the proper hepatic artery using Infusaid. For the other cases, ADM and CDDP were infused repeatedly with single-shot type Infuse-a port. Intra-arterial infusion chemotherapy is very useful because treatment in the outpatient clinics is possible over the longterm, and it is possible for patients receiving the therapy to maintain quality of life.
 ...
PMID:[Evaluation of long survival cases treated with intra-arterial cancer chemotherapy using implantable reservoirs]. 252 43

Between April 1979 and March 1987 24 patients underwent 26 hepatic resections. Colorectal liver metastases constituted the largest group (n = 18), followed by hepatocellular carcinoma (n = 2), Echinococcal liver cyst (n = 1), cholangiocarcinoma (n = 1), and leiomyosarcoma (n = 1). The mean age was 41.8 +/- 14.6 years (range: 23-69 years). Fifteen women and nine men comprised the group. The operative morbidity was 21 per cent, the 30-day operative mortality was 8 per cent (two deaths). Both operative deaths occurred in patients with colorectal liver metastases. The 18 patients with colorectal liver metastases included ten women and eight men. The mean age was 59.1 +/- 6.5 years (range: 46-69 years). There were seven synchronous and 11 metachronous liver metastases. Carcinoembryonic antigen (CEA) was found elevated in 14 of the original primary colonic carcinomas, and in all but one patient with metachronous liver metastases. The mean time from colorectal carcinoma resection to occurrence of metachronous metastases was 17.1 +/- 5.8 months. To date, 10 patients have had recurrences of liver metastases after hepatic resection for colorectal liver metastases. The mean time of recurrence was 12.6 +/- 11.9 months. The size of the metastases was 3.8 +/- 3.2 cm (range: 0.2-17 cm). The mean number of lesions present was 1.5 +/- 1.0. The 1 year and 2 year actuarial survival rates were 87.5 and 43.8 per cent respectively. The longest survivor is alive 54 months after his hepatic resection for colorectal liver metastases and remains to this date disease free.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Hepatic resections: an eight year experience at a community hospital. 283 15

A pilot study was designed to evaluate the efficacy of high-dose FUDR administered through the hepatic artery for the treatment of cancer involving the liver. Three dose schedules were used beginning with a dose of 0.5 mg FUDR/kg/day for 2 weeks followed by normal saline infusion for 2 weeks (schedule A). Elevation of serum bilirubin was the sole indication to deescalate to schedule B (0.3 mg FUDR/kg/day for two weeks followed by saline infusion for 4 weeks). Tolerance to this schedule escalated the patient to schedule C (0.5 mg FUDR/kg/day for 2 weeks followed by normal saline infusion for 4 weeks). Eighteen patients were treated, sixteen with metastatic colon cancer, one with metastatic leiomyosarcoma, and one with hepatoma. The patient with hepatoma developed progressive disease after one cycle of therapy. Of the 17 patients with metastatic cancer only 5 patients failed therapy yielding a 70% response rate. High-dose FUDR was well tolerated with only six patients requiring deescalation to schedule B. Elevation of alkaline phosphatase and glutamic oxaloacetic transaminase was universal. Two patients developed peptic ulceration. Sclerosing cholangitis was not observed. We conclude that high-dose FUDR administered through the hepatic artery is as safe as conventional dose infusion therapy but probably not more effective. The safety of high-dose FUDR infusion therapy suggests that sclerosing cholangitis is association with hepatic arterial infusion therapy is not related to the FUDR dose.
 ...
PMID:Good tolerance to high-dose hepatic arterial infusion therapy. 294 73

Hypoglycemia associated with nonislet cell tumor was found in 13 dogs. In each dog, clinical signs were related directly to adrenergic and neuroglucopenic effects of hypoglycemia and included collapsing episodes, tremors, restlessness, weakness, and grand mal seizures that were responsive to glucose administration. Eight of the dogs had hepatocellular carcinoma; surgical resection of the tumor achieved remission of clinical signs in 3 of these dogs. Other hepatic tumors associated with hypoglycemia included leiomyosarcoma and hemangiosarcoma involving solitary lobes of the liver. Nonhepatic tumors included splenic hemangiosarcoma, diffuse metastatic melanoma, and salivary gland adenocarcinoma.
 ...
PMID:Hypoglycemia associated with nonislet cell tumor in 13 dogs. 298 Dec


1 2 3 4 5 Next >>